(CBLS) Elevation Series Trust - Ratings and Ratios

Exchange: NYSE ARCA • Country: USA • Currency: USD • Type: Etf • ISIN: US53656F6491

CBLS: Long Positions, Short Positions, Hedged Equities

The Elevation Series Trust (CBLS) is an actively managed equity ETF that employs a dual strategy of investing in securities with strong financials, undervaluation, and growth potential, while simultaneously shorting securities expected to decline. This approach aims to capitalize on both upward and downward market movements.

The fund maintains a significant equity exposure, with a minimum of 80% of its net assets, plus borrowings for investment purposes, allocated to equity securities, including common stocks and depositary receipts. This indicates a substantial commitment to the equity market, tempered by the advisers selective approach to stock picking and hedging.

From a technical standpoint, the ETF is currently trading at $28.34, above its 20-day, 50-day, and 200-day simple moving averages (SMA) of $27.37, $26.51, and $26.16, respectively. The Average True Range (ATR) stands at 0.28, indicating a daily volatility of 1.00%. Given its proximity to the 52-week high of $28.76 and distance from the 52-week low of $23.97, the ETF appears to be in an upward trend. The SMAs suggest a bullish short to medium-term outlook.

Fundamentally, the ETF has $41.80M in Assets Under Management (AUM), indicating a relatively modest size. While not exceptionally large, it is sufficiently sizable to suggest a viable investment vehicle.

Forecast: Based on the technical indicators, the upward trend is likely to continue, with potential resistance at the 52-week high of $28.76. If the ETF breaks through this level, it may signal further growth. Conversely, a drop below the 20-day SMA could indicate a reversal. With its active management strategy and current market positioning, a reasonable forecast is for the ETF to potentially reach $30.00 within the next few months, assuming the advisers stock selection and hedging strategies remain effective. However, failure to break through the current 52-week high could result in consolidation around the current price levels.

Additional Sources for CBLS ETF

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle

CBLS ETF Overview

Market Cap in USD 43m
Category Equity Hedged
TER 2.59%
IPO / Inception 2020-11-12

CBLS ETF Ratings

Growth Rating 30.9
Fundamental -
Dividend Rating 50.3
Rel. Strength -0.07
Analysts -
Fair Price Momentum 25.94 USD
Fair Price DCF -

CBLS Dividends

Dividend Yield 12m 0.70%
Yield on Cost 5y 0.95%
Annual Growth 5y 46.06%
Payout Consistency 100.0%
Payout Ratio %

CBLS Growth Ratios

Growth Correlation 3m 86.8%
Growth Correlation 12m 70%
Growth Correlation 5y 8.9%
CAGR 5y 7.68%
CAGR/Max DD 5y 0.23
Sharpe Ratio 12m 1.07
Alpha 0.77
Beta 0.862
Volatility 10.28%
Current Volume 0.2k
Average Volume 20d 4.1k
What is the price of CBLS shares?
As of June 19, 2025, the stock is trading at USD 28.32 with a total of 199 shares traded.
Over the past week, the price has changed by +0.69%, over one month by +0.30%, over three months by +7.55% and over the past year by +10.24%.
Is Elevation Series Trust a good stock to buy?
Neither. Based on ValueRay´s Analyses, Elevation Series Trust is currently (June 2025) neither a good nor a bad stock to buy. It has a ValueRay Growth Rating of 30.85 and therefor a technical neutral rating according to historical growth.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of CBLS is around 25.94 USD . This means that CBLS is currently overvalued and has a potential downside of -8.4%.
Is CBLS a buy, sell or hold?
Elevation Series Trust has no consensus analysts rating.
What are the forecasts for CBLS share price target?
According to our own proprietary Forecast Model, CBLS Elevation Series Trust will be worth about 29.2 in June 2026. The stock is currently trading at 28.32. This means that the stock has a potential upside of +2.93%.
Issuer Target Up/Down from current
Wallstreet Target Price - -
Analysts Target Price - -
ValueRay Target Price 29.2 2.9%